Non-V600 mutations comprise approximately 35% of all BRAF mutations in cancer. Many of these mutations have been identified as oncogenic drivers and can be classified into three classes according to ...
Zero Treatment Related Adverse Events observed during Cohort 7 (37mg capsules) DLT period –--Cohort 7 Pharmacokinetic (PK) ...
CAMBRIDGE, Mass., Oct. 12, 2023 /PRNewswire/ -- Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, today presented ...
Effect of 2G8, a TGF-beta-R2 inhibitor, on TGF-beta signaling and migration in an immunocompetent pancreatic cancer model. Background: Chemokine receptors have been shown to regulate the progression ...
Many cancers harbor pro-proliferative mutations of the mitogen-activated protein kinase (MAPK) pathway. In BRAF-driven melanoma cells treated with BRAF inhibitors, subpopulations of cells escape ...
Psoriasis is characterized by hyperproliferation of keratinocytes and increased expression of integrins, but the pathological signaling pathway remains unknown. In August 15 Journal of Clinical ...
Pasithea Therapeutics Corp ( ($KTTA) ) has shared an update. Pasithea Therapeutics announced positive interim Phase 1 data for PAS-004, showing ...
A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback